Modus Therapeutics participates in FS markets Investment Meeting-Live on September 23rd
On Thursday, 23 September 2021 at 5.30 pm, Modus Therapeutics AB (“Modus”) will participate in FS Markets Investerarmötet-Live (Investment Meeting-Live). Modus CEO John Öhd will present the company and discuss upcoming plans.
Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
Investor Meeting-Live is a live webcast seminar. The presentation will be followed by a question-and-answer session where you can ask questions directly in the chat. You can also email questions in advance or during the presentation to info@fsmarkets.com.
Time: Thursday 23 September at 17.30-18.00.
You can register for the seminar here.
FS Markets' recurring Investor Meeting-Live is a collaboration between FS Markets and Direkt Studios. More information can be found here.
For more information on Modus Therapeutics, please contact:
John Öhd, VD, Modus Therapeutics
Telefon: +46 (0) 70 766 80 97
E-post: john.ohd@modustx.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
About Modus Therapeutics and sevuparin
Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.